Prognostic utility of biomarker growth differentiation factor-15 in patients with acute decompensated heart failure

Acta Cardiologica

Volumn 71, Issue 5, 2016, Pages 587-595

  Jankovic Tomasevic, Ruzica ^a   Pavlovic, Sinisa U ^b   Jevtovic Stoimenov, Tatjana ^c   Apostolovic, Svetlana ^a   Stanojevic, Dragana ^a   Jovanovic, Ivan ^c   Koracevic, Goran ^a   Djordjevic Radojkovic, Danijela ^a   Damjanovic, Miodrag ^a   Salinger Martinovic, Sonja ^a   Pavlovic, Milan ^a  

^a CLINICAL CENTER NIS   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF NI   (Serbia)

Author keywords

Acute decompensated heart failure; Biomarker; GDF 15; Mortality; Prognosis

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; SODIUM; TROPONIN; UREA; GDF15 PROTEIN, HUMAN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; ACUTE DISEASE; BIOASSAY; BLOOD; CASE CONTROL STUDY; HEART FAILURE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; AGED; BIOMARKERS; CASE-CONTROL STUDIES; ENDPOINT DETERMINATION; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; MALE; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84990228344     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.2143/AC.71.5.3167503     Document Type: Article

References (30)

1. Ponikowski P, Anker SD, AlHabib KF, Covie MR, Force T, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Silwa K, Filippatos G. Heart failure. Preventing disease and death worldwide. http://www.escardio.org/static_ file/Escardio/Subspecialty/HFA/ WHFA-whitepaper-15-May-14.pdf.
2. McMurray V, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787-847.
3. Cook C, Cole G, Asaria P, Jabbour, Francis DP. The annual economic burden of heart failure. Int J Cardiol 2014; 171: 368-76.
4. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-ß superfamily. Proc Natl AcadSci USA 1997; 94: 11514-9.
5. Ho JE, Wang TJ. Growth differentiation factor 15: acanary in a coal mine? ClinChem 2012; 58: 3-5.
6. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, Metz J, Kinscherf R. Involvement of growth differentiation factor-15/ macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 2004; 318: 325-33.
7. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351-60.
8. Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle. ClinChem 2013; 59: 1550-2.
9. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002; 359: 2159-63.
10. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H, Olsson K, Wilkins MR, Gibbs JS, Hoeper MM, Wollert KC. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J RespirCrit Care Med 2008; 178: 534-41.
11. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC. Growth differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009; 30: 2346-53.
12. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: theRancho Bernardo Study. Circulation 2011; 123: 2101-10.
13. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007; 28: 2858-65.
14. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007; 115: 962-71.
15. Eggers KM, Kempf T, Lagerqvist B, Lindhal B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P, Wollert KC, Wallentin L. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. CircCardiovascGenet 2010; 3: 88-96.
16. Damman P, Kempf T, Windhausen F, van Straalen JP, Guba-Quint A, Fischer J, Tijssen JGP, Wollert KC, de Winter RJ, Hirsch A; ICTUS investigators. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol 2014; 172: 356-63.
17. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosisin the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-95.
18. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am CollCardiol 2007; 50: 1054-60.
19. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. ClinChem 2007; 53: 284-91.
20. Stahrenberg R, Edelmann F, Mende M, Kockskamper A, Dungan HD, Luers C, Binder L, Hermann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur Heart J 2010; 12: 1309-16.
21. Cotter G, Voors AA, Prescott M, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Milo O, Hua TA, Qian M, Severin TM, Teerlink JR, Metra M, Davison BA. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail 2015; 17: 1133-43.
22. Smilde TDJ, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-80.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
24. Apostolovic S, Stanojevic D, Jankovic- Tomaševic R, Pavlovic M, Tomasevic M, Loncar G, Putnikovic B, Tahirovic E, Inkrot S, Dungen HD. Growth differentiation factor 15 during optimization of beta blocker therapy in chronic heart failure. CIBIS ELD study. Eur J Heart Fail 2012; 11 (Abstract Supplement S1): S45. http://onlinelibrary.wiley.com/ doi/10.1093/eurjhf/hss006/epdf
25. Foley PW, Stegemann B, Ng K, Ramachandran S, Proudler A, Frenneaux MP, Ng LL, Leyva F. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J2009; 30: 2749-57.
26. Lok DJ, Klip IJT, Lok SI, Badings E, de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen J, van der Meer P. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013; 112: 831-7.
27. Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, Kusaka H, Tokitsu T, Rokutanda T, Araki S, Tsujita K, Tanaka T, Yamamuro M, Kojima S, Tayama S, Kaikita K, Hokimoto S, Ogawa H. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014; 30: 338-44.
28. Stiermaier T, Adams V, Just M, Blazek S, Desch S, Schuler G, Thiele H, Eitel I. Gorwth differentiation factor-15 in Takotsubo cardiomyopathy: Diagnostic and prognostic value. Int J Cardiol 2014; 173: 424-9.
29. Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, van der Weide P, Klöpping C, Kirkels JH, Lahpor JR, Doevendans PA, de Jonge N, de Weger RA. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012; 14: 1249-56.
30. Mueller T, Leitner I, Egger M, Haltmayer M, Dieplinger B. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. ClinChimActa 2015; 445: 155-60.